Document Detail

Anti-breast cancer potential of daidzein in rodents.
MedLine Citation:
PMID:  23227466     Owner:  NLM     Status:  MEDLINE    
AIMS: This study was carried out to explore anti-breast cancer potential of isoflavone daidzein or its related compounds using appropriate animal models and their anti-tumor mechanism.
MAIN METHODS: Daidzein or its major metabolite equol at a dose molar equivalent to tamoxifen [1.0 mg(2.7 μmol)/kg or 10 mg (27 μmol)/kg/day] was treated orally to rats bearing 7,12-dimethylbenz(a)anthracene(DMBA)-induced mammary tumors or ovariectomized athymic nude mice implanted with human MCF-7 breast cancer xenograft and an estrogen pellet. The growth of tumors was monitored for several weeks after the treatment. The cell-cycle and apoptotic stages in mammary tumors collected from rats were analyzed by flow cytometry. Immunohistochemistry analysis was also used to determine the expression of caspase-3.
KEY FINDINGS: Oral treatment with daidzein or equol at a human equivalent dose suppressed the growth of both DMBA-induced mammary tumors and human MCF-7 breast cancer xenografts in rodents, the inhibitory activity being superior to that of genistein or tamoxifen. Strong apoptosis induced by daidzein or equol contributes to the anti-tumor potential.
SIGNIFICANCE: Daidzein and its metabolite equol showed the potential of inhibiting the growth of mammary tumors in rodents. Daidzein or equol could be used as a core structure to design new drugs for breast cancer therapy. Our results indicate that consumption of daidzein may protect against breast cancer.
Xiaoping Liu; Naomi Suzuki; Y R Santosh Laxmi; Yoshinori Okamoto; Shinya Shibutani
Related Documents :
11902306 - Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic l...
21532876 - Giant tricholemmal squamous cell carcinoma with cranial infiltration.
15700256 - Immune thrombocytopenia following successful treatment of cancer in children.
21935866 - β-catenin expression in in situ and infiltrative ductal carcinomas of the breast.
24451146 - Assessment of osteopontin in early breast cancer: correlative study in a randomised cli...
19117016 - Vascular endothelial growth factor-c and -d expression correlates with lymph node micro...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Life sciences     Volume:  91     ISSN:  1879-0631     ISO Abbreviation:  Life Sci.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-12-03     Completed Date:  2012-12-10     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  0375521     Medline TA:  Life Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  415-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Growth Inhibitors / therapeutic use*
Isoflavones / therapeutic use*
Mammary Neoplasms, Experimental / drug therapy*,  pathology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Growth Inhibitors; 0/Isoflavones; 6287WC5J2L/daidzein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High and low radioiodine doses to indicate a simple renal cyst.
Next Document:  Bioactivity of enoxaparin in critically ill patients with normal renal function.